TT-P34 / Teitur Trophics - LARVOL DELTA

Clinical Evaluation of TT-P34: Exploring Safety and CSF Exposure in Parkinson’s Disease Patients (MDS Congress 2026) - No abstract available

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

NeuraLight and Teitur Trophics Announce Collaboration to Use Precision Biomarkers in TT-P34 Parkinson’s Disease Clinical Trial (Businesswire) - "The use of NeuraLight's precision brain function biomarkers in Teitur's upcoming clinical trial is intended to provide quantitative assessment of disease-relevant neural pathway function, and to support the evaluation of TT-P34's potential as a disease-modifying therapy in Parkinson's disease."

Commercial • New trial • Parkinson's Disease

Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases (PRNewswire) - “Teitur Trophics…announces the completion of a €28M Series A financing. The financing was co-led by Sunstone Life Science Ventures and Sound Bioventures, with participation from new investors, Industrifonden, Innovestor's Life Science Fund and P53 Invest. The proceeds will enable Teitur to progress its lead drug candidate, TT-P34, from candidate selection into clinical development, including a Phase 1b clinical study in neurodegenerative diseases….TT-P34 is administered subcutaneously and has shown potent, brain specific effects in animal models for Huntington's Disease, Parkinson's Disease and Frontotemporal Dementia.”

Commercial • CNS Disorders • Frontotemporal Lobar Degeneration • Huntington's Disease • Parkinson's Disease